Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 11/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20528027 | 1.00 | CALML3 (0.57) | CALML3CYP3A4CYP2C9CYP2D6MAOA | |
| SCHEMBL18786544 | 1.00 | CALML3 (0.57) | CALML3CYP3A4CYP2C9CYP2D6MAOA | |
| SCHEMBL18790187 | 0.91 | CALML3 (0.55) | CALML3CYP3A4CYP2C9CYP2D6MAOA | |
| SCHEMBL5233140 | 0.87 | CYP3A4 (0.42) | CALML3CYP3A4CYP2C9 | |
| SCHEMBL18770261 | 0.84 | CALML3 (0.55) | CALML3CYP3A4CYP2C9CYP2D6MAOA | |
| SCHEMBL18786545 | 0.84 | CYP3A4 (0.56) | CALML3CYP3A4CYP2D6MAOA | |
| SCHEMBL18786431 | 0.84 | CALML3 (0.55) | CALML3CYP3A4CYP2C9CYP2D6MAOA | |
| SCHEMBL18786438 | 0.84 | CYP3A4 (0.56) | CALML3CYP3A4CYP2D6MAOA | |
| SCHEMBL20528013 | 0.83 | CALML3 (0.74) | CALML3CYP3A4CYP2C9CYP2D6MAOA | |
| SCHEMBL29432578 | 0.83 | CALML3 (0.74) | CALML3CYP3A4CYP2C9CYP2D6MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061777-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2021-03-04 | — | — | US | disclosed |
| WO-2017070024-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017066964-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061777-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | OXA1L, ERAL1, TBCD | CALML3 3904/4885CYP3A4 1996/4885CYP2C9 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.